Studies have reported that only approximately 5% of patients with metastatic triple-negative BCa obtain a positive response to PD-1/PD-L1 blockade [6, 7], and the response rate seems to increase to 19–23% upon selection of patients with a PD-L1-positive tumor microenvironment (TME) [8, 9]. This evidence concerns the gene CD274 and neoplasm.